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Methods: Serum biomarkers levels were measured in 18 patients
with HH at time of diagnosis and after iron depletion. Iron depletion
was considered to be achieved when ferritin level was below 50
microg/l. For each patient, demographic data were collected and
the global articular pain (0-100 mm VAS) was assessed before
and after iron depletion. Medians and ranges were reported for
non-normally distributed data and means ± SD were reported
for normally distributed data. Statistical analyses were performed
using the Wilcoxon and the Mann-Whitney tests.
Results: All patients (10 males and 8 females, mean age 48
(11) years)) were homozygous for the C282Y mutation. Ferritin
level before iron removal was 627.5 (133-3276) microg/l and
duration of the iron depletion phase was 295 (70-670) days.
Global joint pain (VAS) did not correlate with ferritin concentration
(p=0.59) and did not decrease after iron depletion: 43±15mm
vs. 36±17mm (p=0.14). Both serum levels of Coll 2-1 (marker
of collagen degradation) and CPII (marker of collagen synthesis)
signiﬁcantly increased after iron depletion: 80.19 (55,6-113,5) nM
vs. 96 (48,83-136,3) nM (p=0,03) and 731,46 (374,28-1012,37)
ng/ml vs. 812,82 (535,81-1165,63) ng/ml (p=0,03), respectively.
Levels of the other biomarkers were not modiﬁed by iron depletion.
The severity of iron overload, as assessed by the serum ferritin
level at diagnosis, was signiﬁcantly correlated with the serum
level of HA (marker of synovium) measured before iron depletion
(r=0,60; p=0,01).
Conclusions: The results of this study suggest that i) Iron deple-
tion in patients with genetic hemochromatosis is associated with
an increased cartilage matrix turnover; ii) Synovium might play a
role in the pathophysiology of hemochromatosis arthropathy.
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Purpose: The annual incidence of acute knee injury in the United
States is estimated to be 300 cases per 100,000 population.
Response to surgical treatment varies and currently there is a
general lack of objective evidence to support a protective role
of repair or reconstructive surgery against osteoarthritis (OA)
development. Even after surgery, on average, osteoarthritis, pain,
and functional impairment occur 10-20 years after severe knee
joint injury in 50% of knee injury patients. We hypothesize that
after joint injury, such as trauma or anterior cruciate ligament
damage, the inﬂammatory cytokines produced lead to irreversible
damage to the cartilage and possibly the bone microstructure
resulting in reduced joint functionality and eventual early onset
OA. Here we investigate the changes in biomarkers in the synovial
ﬂuid (SF) of a small intra-articular IL-1Ra intervention study (n=11)
at time of injury (baseline) and one month later (follow-up) when
the patient underwent reconstructive surgery.
Methods: SFs were collected under IRB approval at baseline and
at follow-up from an IL-1Ra intervention study of 11 patients: after
initial SF collection, 6 patients were treated with a single dose of
150 mg IL-1Ra (Anakinra) and 5 placebo patients were treated
with saline. Changes in biomarkers (see Table) were determined
using ELISA assays and all data were analyzed using Wilcoxon
signed rank test.
Results: We investigated a wide range of biomarkers in SF, see
table. There were signiﬁcant increases in the SF levels of colla-
gen type I/II related markers (CTxI, NtxI, CtxII, and C1,2C) from
baseline to follow-up. In contrast, SF proteoglycan loss was ele-
vated after acute injury then decreased signiﬁcantly by one month
as represented by GAG. SF markers of protein age indicative of
the turnover state (racemized D-Asp/protein and D-Ser/protein)
increased signiﬁcantly from baseline to follow-up.
Conclusions: We investigated a wide range of biomarkers in the
SF of acute injury patients to better understand the effects of the
early inﬂammatory events upon joint damage after acute injury.
We observed signiﬁcant early proteoglycan loss which decreased
with time, and an increase in collagen loss. This pattern of initial
proteoglycan loss followed by collagen loss is characteristic of
pro-inﬂammatory induced cartilage damage. Markers of protein-
age compatible with degeneration of older and deeper cartilage
macromolecules were also elevated. These data suggest that there
is signiﬁcant cartilage and bone damage during the initial weeks
after acute injury which left untreated could enhance the risk of
later OA development. These data also suggest that speciﬁcally
targeting the early inﬂammatory events after acute injury would
have potential long term beneﬁts.
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Purpose: This study focuses on the development of an drug
activity biomarker of aggrecanase activity in osteoarthritis (OA).
Degradation of cartilage matrix proteins, such as aggrecan, is one
of the mechanisms that leads to cartilage dysfunction. Attempts
to monitor this degradation require a well-validated biomarker as-
say, especially to decrease lengthy OA clinical trials. This study
centers on a biomarker which will respond in a dose-dependent
manner to small molecule aggrecanase inhibitors in different bi-
ological models. The biomarker centers on the aggrecan degra-
dation (peptide fragment ARGSVIL) resulting from aggrecanase
cleavage at the 373Glu - 374Ala bond in the interglobular domain
of aggrecan. Quantiﬁcation of levels of this biomarker could allow
potential assessment of patient differentials, such as inter- and
intra-variability in patient populations, efﬁciency of drug inhibition,
and a potential for diagnostic/prognostic capabilities or patient
stratiﬁcation/selection for tailored therapeutics.
Methods: Here, we analyze biological samples from bovine and
human articular cartilage explants and human OA urine to as-
sist in understanding the values of the ARGSVIL biomarker in
these tissues, inter- and intra-patient variability, and the ability to
inhibit aggrecan degradation via use of inhibitor compounds. The
analysis of these biological samples is performed using a novel
immunoafﬁnity LC/MS/MS assay or a recently developed ELISA
assay based on an improved ARGS neoepitope antibody (BC3-
C2) that was developed to measure levels of the ARGSVIL peptide
biomarker.
